{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?AnswerDate=2018-01-24&version=3", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?AnswerDate=2018-01-24&version=3", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?AnswerDate=2018-01-24&_metadata=all&version=3", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&AnswerDate=2018-01-24&version=3", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?AnswerDate=2018-01-24&version=3", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?AnswerDate=2018-01-24&version=3", "items" : [{"_about" : "http://data.parliament.uk/resources/827953", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/827953/answer", "answerText" : {"_value" : "
On 3 November, the Government published its response to the Accelerated Access Review. It set out plans to give patients quicker access to life-changing treatments; and, make the United Kingdom the best place in the world for industry to invest and innovate. From April 2018, the new Accelerated Access Pathway will mean selected products with the greatest potential to change lives could be available up to four years earlier by reducing the time taken to negotiate the evaluation and financial approvals necessary before the National Health Service can purchase them.<\/p>
<\/p>
Following a public consultation, NHS England and the National Institute for Health and Care Excellence introduced new arrangements for the appraisal and funding of cancer drugs in July 2016. The new arrangements, including the Cancer Drugs Fund, are designed to ensure that patients benefit from faster access to the most promising new drugs while delivering better value for money for the taxpayer.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-01-30", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-01-30T12:03:20.377Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-01-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Prescription Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans he has to reform the way in which medicines are (a) appraised and (b) funded to ensure that patients have timely access to life-extending medicines at a price that is affordable for the NHS and taxpayer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"} } , "tablingMemberConstituency" : {"_value" : "Leeds North West"} , "tablingMemberPrinted" : [{"_value" : "Alex Sobel"} ], "uin" : "123913"} , {"_about" : "http://data.parliament.uk/resources/827976", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/827976/answer", "answerText" : {"_value" : "
In July last year the Government set out three principles which will underpin the development of a post-Brexit regulatory system for medicines and devices: patients should not be disadvantaged; innovators should be able to access the United Kingdom market as quickly and simply as possible; and we will continue to play a leading role in both Europe and the world in promoting public health.<\/p>
<\/p>
As the Prime Minister has stated, the UK is fully committed to continuing the close working relationship with our European partners. In this context, the UK will be working with the European Union to agree how best to continue cooperation in the field of medicines regulation, for the benefit of public health and safety in both the UK and the EU Member States.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"} } , "answeringMemberConstituency" : {"_value" : "Thurrock"} , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"} , "dateOfAnswer" : {"_value" : "2018-01-30", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-01-30T13:59:25.82Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-01-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that licensing for new drugs in the UK is not slowed down by the UK leaving the EU and the European Medicines Agency.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"} } , "tablingMemberConstituency" : {"_value" : "Leeds North West"} , "tablingMemberPrinted" : [{"_value" : "Alex Sobel"} ], "uin" : "123936"} , {"_about" : "http://data.parliament.uk/resources/828115", "AnsweringBody" : [{"_value" : "Department for Education"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/828115/answer", "answerText" : {"_value" : "
The Higher Education Statistics Agency (HESA) collects and publishes information on enrolments and qualifications obtained at UK higher education institutions. The latest statistics, referring to the 2016/17 academic year, were published on 11 January 2018 at the following link: https://www.hesa.ac.uk/news/11-01-2018/sfr247-higher-education-student-statistics<\/a>.<\/p> <\/p> The number of qualifiers from higher education courses who were domiciled in Jarrow constituency, South Tyneside local authority, the North East region and England, prior to study in the 2016/17 academic year, has been provided in the table below.<\/p> <\/p> Higher Education qualifiers1)2)3)<\/sup> by place of domicile prior to study4)<\/sup><\/strong><\/p> UK Higher Education Institutions<\/p> Academic year 2016/17<\/p> Academic year<\/p><\/td> Jarrow constituency<\/p><\/td> South Tyneside local authority<\/p><\/td> North East region<\/p><\/td> England Total<\/p><\/td><\/tr> 2016/17<\/p><\/td> 615<\/p><\/td> 1,080<\/p><\/td> 20,905<\/p><\/td> 459,425<\/p><\/td><\/tr><\/tbody><\/table> Source: Department for Education analysis of HESA\u2019s Student Record<\/p> Notes:<\/p>